Predicting risk for diabetes: Choosing (or building) the right model

Annals of Internal Medicine

Volumn 150, Issue 11, 2009, Pages 812-814

  Herman, William H ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE;

BLOOD PRESSURE MONITORING; BODY HEIGHT; DIABETES MELLITUS; EDITORIAL; EXPERIMENTAL MODEL; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SELF EVALUATION; WAIST CIRCUMFERENCE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; UNITED STATES;

DIABETES MELLITUS, TYPE 2; HUMANS; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 66649125311     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-11-200906020-00010     Document Type: Editorial

References (20)

1. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care. 2000;23:1563-1580 [PMID: 11023153]
2. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148:846-854 [PMID: 18519930]
3. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G; Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord. 2000;24 Suppl 3:S6-11. [PMID: 11063279]
4. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544 [PMID: 9096977]
5. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350 [PMID: 11333990]
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. [PMID: 11832527]
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077 [PMID: 12086760] (Pubitemid 34680970)
8. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105 [PMID: 16997664]
9. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, et al; Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26:36-47. [PMID: 12502656]
10. Third National Health and Nutrition Examination Survey. Predicting impaired glucose tolerance using common clinical information: data from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2003;26:2058-2062 [PMID: 12832313]
11. Meigs JB, Williams K, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, et al. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care. 2004;27:1417-1426 [PMID: 15161798] (Pubitemid 38679992)
12. Colagiuri S, Hussain Z, Zimmet P, Cameron A, Shaw J; AusDiab. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care. 2004;27:367-371 [PMID: 14747215]
13. Tabaei BP, Engelgau MM, Herman WH. A multivariate logistic regression equation to screen for dysglycaemia: development and validation. Diabet Med. 2005;22:599-605. [PMID: 15842515] (Pubitemid 40593136)
14. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med. 2002;136:575-581 [PMID: 11955025]
15. Lindström J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26:725-731 [PMID: 12610029] (Pubitemid 36929335)
16. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et al; The Atherosclerosis Risk in Communities Investigators. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28:2013-2018 [PMID: 16043747]
17. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ. 2009;338:b880. [PMID: 19297312]
18. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age. Diabetes Care. 2005;28:307-311 [PMID: 15677784] (Pubitemid 40170931)
19. Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med. 2009;150:741-751
20. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care. 2004;27:9-12. [PMID: 14693958] (Pubitemid 38196701)